2. Simon L.S., Lanza F.L., Lipsky P.E. et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum. 1998;41(9):1591–602. https://dx.doi.org/10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J.

3. Xu Z., Zhang R., Zhang D. et al. Peptic ulcer hemorrhage combined with acute gout: Analyses of treatment in 136 cases. Int J Clin Exp Med. 2015; 8(4): 6193–99.

4. Haschek and Rousseaux’s handbook of toxicologic pathology. Ed. by Haschek W.M., Rousseaux C.G., Wallig M.A. Academic Press. 2013; 3054 pp. https://dx.doi.org/10.1016/C2010-1-67850-9. ISBN: 978-0-12-415759-0.

5. Villa J., Cano A., Franco D. et al. Relevancia clínica de las interacciones medicamentosas entre antiinflamatorios no esteroideos y antihipertensivos. Atencion Primaria. 2014; 46(9): 464–74. [Villa J., Cano A., Franco D. et al. Clinical relevance of drug interactions between nonsteroidal antiinflammatory drugs (NSAIDs) and antihypertensives. Atencion Primaria = Primary Care. 2014; 46(9): 464–74 (In Spanish)]. https://dx.doi.org/10.1016/j.aprim.2013.11.010.

6. Krum H., Swergold G., Curtis S.P. et al. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: Results from the MEDAL study. J Hypertens. 2009; 27(4): 886–93. https://dx.doi.org/10.1097/HJH.0b013e328325d831.

7. Остроумова О.Д., Куликова М.И. Лекарственно-индуцированная артериальная гипертония. Системные гипертензии. 2019; 16(2): 32–41. [Ostroumova O.D., Kulikova M.I. Drug-induced arterial hypertension. Sistemnyye gipertenzii = Systemic Hypertension. 2019; 16(2): 32–41 (In Russ.)]. https://dx.doi.org/10.26442/2075082X.2019.2.180164. EDN: YBOMKF.

8. Lovell A.R., Ernst M.E. Drug-induced hypertension: Focus on mechanisms and management. Curr Hypertens Rep. 2017; 19(5): 39.https://dx.doi.org/10.1007/s11906-017-0736-z.

9. Cannon C.P., Curtis S.P., FitzGerald G.A. et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: A randomised comparison. Lancet. 2006; 368(9549): 1771–81. https://dx.doi.org/10.1016/S0140-6736(06)69666-9.

10. Каратеев А.Е. Дестабилизация артериальной гипертензии как осложнение терапии нестероидными противовоспалительными препаратами: значение проблемы. Современная ревматология. 2018; 12(2): 64–72. [Karateev A.E. Destabilized hypertension as a complication of therapy with nonsteroidal anti-inflammatory drugs: The importance of the problem. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2018; 12(2): 64–72 (In Russ.)]. https://dx.doi.org/10.14412/1996-7012-2018-2-64-72. EDN: XPPNNR.

11. Stamp L.K., Chapman P.T. Gout and its comorbidities: Implications for therapy. Rheumatology (Oxford). 2013; 52(1): 34–44.https://dx.doi.org/10.1093/rheumatology/kes211.

12. Spieker L.E., Ruschitzka F.T., Luscher T.F., Noll G. The management of hyperuricemia and gout in patients with heart failure. Eur J Heart Fail. 2002; 4(4): 403–10. https://dx.doi.org/10.1016/s1388-9842(02)00086-7.

13. Ватутин Н.Т., Смирнова А.С., Целикова Е.О. Новые возможности в терапии сердечно-сосудистой патологии с использованием колхицина. Архивъ внутренней медицины. 2016; 6(3): 19–24. [Vatutin N.T., Smirnova A.S., Tselikova E.O. New possibilities in the treatment of cardiovascular pathology using colchicine. Arkhiv vnutrenney meditsiny = The Russian Archives of Internal Medicine. 2016; 6(3): 19–24 (In Russ.)]. https://dx.doi.org/10.20514/2226-6704-2016-6-3-19-24. EDN: VZTUHR.

14. Lucas G.N.C., Leitao A.C.C., Alencar R.L. et al. Pathophysiological aspects of nephropathy caused by non-steroidal anti-inflammatory drugs. J Bras Nefrol. 2019; 41(1): 124–30. https://dx.doi.org/10.1590/2175-8239-JBN-2018-0107.

15. Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: An update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci.. 2013; 16(5): 821–47. https://dx.doi.org/10.18433/j3vw2f.

16. Harirforoosh S., Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf. 2009; 8(6): 669–81.https://dx.doi.org/10.1517/14740330903311023.

17. Ejaz P., Bhojani K., Joshi V.R. NSAIDs and kidney. J Assoc Physicians India. 2004; 52: 632–40.

18. Andrassy K.M. Comments on «KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease». Kidney Int. 2013; 84(3): 622–23. https://dx.doi.org/10.1038/ki.2013.243.

19. UpToDate. Gaffo A.L. Treatment of gout flares. 2022. URL: https://www.uptodate.com/contents/treatment-of-gout-flares (date of access – 01.03.2023).

20. Bardin T., Richette P. Impact of comorbidities on gout and hyperuricaemia: An update on prevalence and treatment options. BMC Med. 2017; 15(1): 123. https://dx.doi.org/10.1186/s12916-017-0890-9.

21. Фингер Д.Р. Гипоурикемические средства и колхицин. В кн.: Секреты ревматологии. Под ред. Стерлинга Дж. Уэста; пер. с англ. под ред. О.М. Лесняк. М.: ГЭОТАР-Медиа. 2018; с. 683–690. [Finger D.R. Hypouricemic drugs and colchicine. In: Rheumatology secrets. Ed. by Sterling J. West; translation from English, ed. by O.M. Lesniak. Moscow: GEOTAR-Media. 2018; pp. 683–690 (In Russ.)]. ISBN: 978-5-9704-4508-2.

22. Страчунский Л. С., Козлов С. Н. Глюкокортикоидные препараты. Методическое пособие. Смоленск: Смоленская государственная медицинская академия. 1997; 63[1] с. [Strachunsky L.S., Kozlov S.N. Glucocorticoids. Smolensk: Smolensk State Medical Academy. 1997; 63[1] pp. (In Russ.)]. ISBN: 5-86239-006-5

23. Прилепская О.А., Дурова М.В., Лебедев И.А. Особенности медикаментозной терапии болевого синдрома у пациентов с терминальной почечной недостаточностью, получающих терапию хрониогемодиализом. Медицинский алфавит. 2017; 1(2): 9–12. [Prilepskaya O.A., Durova M.V., Lebedev I.A. Features of drug therapy of pain syndrome in patients with terminal renal failure receiving chroniohemodialysis therapy. Meditsinskiy alfavit = Medical Alphabet. 2017; 1(2): 9–12 (In Russ.)]. EDN: YSLUYH.

24. LiverTox: Clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Colchicine. 2012. URL: https://www.ncbi.nlm.nih.gov/books/NBK548068/ (date of access – 01.03.2023).

25. LiverTox: Clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Corticosteroids (Updated 2021 May 7). 2012.URL: https://www.ncbi.nlm.nih.gov/books/NBK548400/?rep (date of access – 01.03.2023).

26. Клинические рекомендации. Подагра. Ассоциация ревматологов России. 2018. ID: 251. Доступ: https://legalacts.ru/doc/klinicheskie-rekomendatsii-podagra-utv-minzdravom-rossii/ (дата обращения – 01.01.2023). [Clinical guidelines. Gout. Association of Rheumatologists of Russia. 2018. ID: 251.URL: https://legalacts.ru/doc/klinicheskie-rekomendatsii-podagra-utv-minzdravom-rossii/ (date of access – 01.03.2023).

27. Ушкалова Е.А., Зырянов С.К., Переверзев А.П. Клиническая фармакология нестероидных противовоспалительных средств. Учебное пособие. М.: МИА. 2018; 368 с. [Ushkalova E.A., Zyryanov S.K., Pereverzev A.P. Clinical pharmacology of non-steroidal anti-inflammatory drugs. Tutorial. Moscow: MIA. 2018; 368 pp. (In Russ.)]. ISBN: 978-5-6040008-3-0.

28. Reed G.W., Abdallah M.S., Shao M. et al. Effect of aspirin coadministration on the safety of celecoxib, naproxen, or ibuprofen. J Am Coll Cardiol. 2018; 71(16): 1741–51. https://dx.doi.org/10.1016/j.jacc.2018.02.036.

29. Roberts W. N. Joint aspiration or injection in adults: Technique and indications. 2019. URL: https://www.uptodate.com/contents/joint-aspiration-or-injection-in-adults-technique-and-indications (date of access – 01.03.2023).

30. Medsafe: New Zealand Medicines and Medical Devices Safety Authority. Dabigatran and gout or gout-like symptoms. 2018.URL: https://www.medsafe.govt.nz/safety/ews/2018/DabigatranAndGout.asp (date of access – 01.03.2023).

31. Hak A.E., Curhan G.C., Grodstein .F, Choi H.K. Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis. 2010; 69(7): 1305–9. https://dx.doi.org/10.1136/ard.2009.109884.

32. Ушкалова Е., Ткачева О., Чухарева Н., Бевз А. Безопасность НПВС и ненаркотических анальгетиков в период беременности и лактации. Врач. 2010; (8): 10–12. [Ushkalova E., Tkacheva O., Chukhareva N., Bevz A. Safety of nonsteroidal anti-inflammatory drugs and nonnarcotic analgesics during pregnancy and lactation. Vrach = The Doctor. 2010; (8): 10–12 (In Russ.)]. EDN: MWJRRH.

33. Koren G., Florescu A., Costei A.M. et al. Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: A meta-analysis. Ann Pharmacother. 2006; 40(5): 824–29. https://dx.doi.org/10.1345/aph.1G428.

34. Rigourd V., De Villepin B., Amirouche A. et al. Ibuprofen concentrations in human mature milk – First data about pharmacokinetics study in breast milk with AOR-10127 «Antalait» study. Ther Drug Monit. 2014; 36(5): 590–96. https://dx.doi.org/10.1097/FTD.0000000000000058.

35. Indraratna P.L., Virk S., Gurram D., Day R.O. Use of colchicine in pregnancy: A systematic review and meta-analysis. Rheumatology (Oxford). 2018; 57(2) :382–87. https://dx.doi.org/10.1093/rheumatology/kex353.

36. Kelly W.N., Fox I.H., Palelleo T.D. Gout and related disorders of purine metabolism. In: Textbook of Rheumatology. WB Saunders. Philadelphia 1989; 1395 pp.

37. Zhuo Y., Cai X., Hou Z. et al. Postoperative recurrent gout flares. J Clin Rheumatol. 2020; 26(5): 197–203.https://dx.doi.org/10.1097/RHU.0000000000001138.

38. Jeong H., Jeon C.H. Clinical characteristics and risk factors for gout flare during the postsurgical period. Adv Rheumatol. 2019; 59(1): 31. https://dx.doi.org/10.1186/s42358-019-0075-7.

39. Craig M.H., Poole G.V., Hauser C.J. Postsurgical gout. Am Surg. 1995; 61(1): 56–59.

40. UpToDate. Muluk V., Cohn S.L., Whinney C. Perioperative medication management. 2022. URL: https://www.uptodate.com/contents/perioperative-medication-management (date of access – 01.03.2023).

41. UpToDate. Axford J.S. Preoperative evaluation and perioperative management of patients with rheumatic diseases. 2020. URL: https://www.uptodate.com/contents/preoperative-evaluation-and-perioperative-management-of-patients-with-rheumatic-diseases#H11 (date of access – 01.03.2023).

42. Springman S., Trapskin P.J., Hennes A. et al. Perioperative medication management. Adult/pediatric. Inpatient/ambulatory clinical practice guideline. University of Wisconsin Hospitals and Clinics Authority. 2020.URL: https://www.uwhealth.org/cckm/cpg/medica (date of access – 01.03.2023).

43. FitzGerald J.D., Dalbeth N., Mikuls T. et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020; 72(6): 744–60. https://dx.doi.org/10.1002/acr.24180.

44. Preoperative Administration of Medicines for Elective Surgery. Canterbury district health board. 2020. URL: https://edu.cdhb.health.nz/Hospitals-Services/Health-Professionals/CDHB-Policies/Fluid-Medication- Manual/Documents/Preopera (date of access – 01.03.2023).

45. Gow P. Treating gout in patients with comorbidities. Int J Clin Rheumtol. 2011; 6(6): 625–33. https://dx.doi.org/10.2217/ijr.11.63.